Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/14-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes hepatic oxidation via CYP3A4 and conjugation; norethindrone primarily hepatic reduction and conjugation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 80-90% bound to SHBG and albumin; Ethinyl estradiol: 97-98% bound to albumin and SHBG
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2.5-4 L/kg; Ethinyl estradiol: 2.5-3 L/kg; clinical meaning: extensive tissue distribution
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: 64%; Ethinyl estradiol: 38-48% (oral, due to first-pass metabolism)
Oral: ~70% due to first-pass metabolism.
No dose adjustment necessary for mild to moderate renal impairment. Avoid use in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential fluid retention and hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease or Child-Pugh Class B and C cirrhosis. For Child-Pugh Class A, use with caution and monitor liver function; no specific dose adjustment guidelines available.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use in children; contraindicated prior to menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; avoid use in elderly due to increased risk of thrombotic and cardiovascular events.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (stroke, MI, DVT/PE),Hepatic neoplasia risk,Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular lesions (retinal thrombosis),Depression,Drug interactions (e.g., rifampin, anticonvulsants)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of DVT/PE,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Liver tumors (benign or malignant) or active liver disease,Hypersensitivity to any component,Age >35 and smoking ≥15 cigarettes/day
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may increase ethinyl estradiol concentrations; avoid excessive consumption. No other significant food interactions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Combination hormonal contraceptives (estrogen-progestin) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of congenital anomalies; however, second and third trimester exposure may increase risks of fetal genital tract abnormalities and possibly other adverse outcomes. Use is not recommended during any trimester.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Combination oral contraceptives may reduce milk production and pass into breast milk. M/P ratio is not well-defined. Use during breastfeeding is generally not recommended; progestin-only contraceptives are preferred.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Ortho-Novum 7/14-21 is contraindicated in pregnancy; no dose adjustment is applicable. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
For Ortho-Novum 7/14-21, a triphasic oral contraceptive containing norethindrone and ethinyl estradiol, counsel patients that missed pills require backup contraception; the risk of venous thromboembolism is highest in the first year of use and in smokers over 35; monitor blood pressure at baseline and follow-up; use with caution in patients with migraine with aura; GI disturbances (vomiting, diarrhea) may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time, starting on the first Sunday after your period begins.,If you miss a pill, refer to the package insert for specific instructions; use backup contraception as directed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve after 3 cycles.,Do not smoke while taking this medication, especially if you are over 35 years old, due to increased risk of blood clots.,Contact your healthcare provider immediately if you experience sudden chest pain, shortness of breath, leg pain or swelling, severe headache, or vision changes.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/14-21 vs AFIRMELLE, answered by our medical review team.
ORTHO-NOVUM 7/14-21 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/14-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/14-21 is: One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/14-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/14-21 is classified as Category C. Combination hormonal contraceptives (estrogen-progestin) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of congenital anomalies; however, . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.